CANCER RESEARCH UK & UCL CANCER TRIALS CENTRE Site Quality Control Checklists – Pharmacy Site File

UKALL14

Site Name:							
	macy Site File – document vers	sion checklist					
Complete 'yes' or 'no' to confirm the presence or absence of each document specified. Any missing documents will be							
provided to you for the Pharmacy SF by UCL CTC following return of this checklist.							
Section	Document Name	Current Version	Date	Present?		Comments	
01	TRIAL MANAGEMENT						
	CTC Contact List	6.0	08feb17	Υ	N \square		
	Site staff delegation log	1.0	08aug11	Υ 🗌	N 🗌		
	Site activation letter	1	1	Y 🗌	N 🗌		
02	ETHICS & REGULATORY APPROV				•		
	*sites must have the initial approval lett	ers, site approval let	tter and all relevant sub	sequent a	pprovals		
	Ethics approval letter (Main REC)	-	13jan10	Y 🗌	N 🗌		
	MHRA approval letter	-	13jan10	Y 🗌	N \square		
		PIS v2 Protocol v2	23feb10 21jun10	Y	N N		
	Amendments– MHRA Approval	Protocol v3 Labelling Protocol v4	17sep10 03nov10 09may12	Y Y Y Y Y Y Y Y Y Y			
	Letters	Protocol v5 Protocol v6 Protocol v6.1 Protocol v7	27sep12 15jul14 11mar15 15nov15	Y			
		Protocol v8 Protocol v9	15Jun16 13Mar17	Y	N		
	Urgent Safety Measure Correspondence	USM email - Protocol v4	24apr12	Y 🗌	N 🗌	Email correspondence sent from CTC 24.04.12 regarding USM	
	Amendments - MREC Approval Letters	Protocol v2 Protocol v3 Consent period Protocol v4 Protocol v5 PIS 4.1 PIS 5 Protocol v6 Protocol v6.1 PIS 5.2, ICF 1.2 Protocol v7 Protocol v8 Protocol v9	07jun10 08sep10 24aug11 16may12 23aug12 17may13 02apr14 09jul14 23feb15 21may15 30sep15 06Jun16	Y			
03	CURRENT PROTOCOL / STUDY IN	IFORMATION					
	Current approved protocol	9	17Feb17	Υ 🗌	N 🗌		
	Current versions of summary of products characteristics: - Mabthera - Kepivance - Oncaspar - Atriance		Jun2016 May2013 Jun2014 Apr2015	Y	N		
	Roche Six Monthly SUSAR reports	-	26may-25nov13 26nov13- 25may14	Y Y Y Y Y Y Y Y Y Y	N		

CANCER RESEARCH UK & UCL CANCER TRIALS CENTRE Site Quality Control Checklists – Pharmacy Site File

UKALL14

Site N	lame:					
Comp	macy Site File – document vers lete 'yes' or 'no' to confirm the pre led to you for the Pharmacy SF by	esence or absen			ied. Ar	ny missing documents will be
-	Document Name	Current Version	Date	Present?		Comments
			26may-17nov14 18nov14- 17may15 18may15- 17nov15	Y Y Y	N N	
04	IMP MANAGEMENT					
	Drug Supply Guidelines	2.1	25feb14	Υ	N \square	
	Drug Accountability logs: - Phase 1 Oncaspar - Phase 1 Rituximab - Phase 2 Nelarabine - Consolidation Oncaspar - Intensification Oncaspar	2.0 2.0 2.0 2.0 2.0	18may15 18may15 18may15 18may15 18may15	Y	N N N N N N N N N N N N N N N N N N N	
	- Palifermin treatment	2.0	18may15	Υ	ΝL	
	Stock Balance Logs:	1.0 1.0 1.0 1.0	18may15 18may15 18may15 18may15	Y		
	Drug order forms: - Oncaspar - Rituximab - Nelarabine - Palifermin	3 1 1 4	11Feb13 Jan10 29Nov10 09sep15	Y	N	
	Rituximab Certificate of Clinical Trial Supply	1	Jan2010	Y 🗌	N 🗌	
	UKALL14 memorandum to Investigators and Pharmacists	-	26jan16	Y 🗌	N 🗌	
	UCL-CTC Pharmacy Notification of Temperature Excursion Form	2.0	25feb14	Y 🗌	N 🗌	
	UCL-CTC Pharmacy Procedure for Reporting Temperature Excursions	1.0	17sep10	Υ□	N 🗌	
	Temperature Monitoring Log Template	1.0	29nov10	Y 🗌	N 🗌	
	Destruction Log Template	1.0	29nov10	Y 🗌	N 🗌	
	IMP Label RA submission form – Oncaspar	-	21oct10	Y 🗌	N 🗌	
	IMP Label RA submission form – Rituximab	-	21oct10	Y 🗌	N 🗌	

CANCER RESEARCH UK & UCL CANCER TRIALS CENTRE Site Quality Control Checklists – Pharmacy Site File

UKALL14

Site N	lame:					
Pharr	nacy Site File – document vers	ion checklist				
	lete 'yes' or 'no' to confirm the pre led to you for the Pharmacy SF by				ied. Ar	ny missing documents will be
Section	Document Name	Current Version	Date	Present?		Comments
	IMP Label RA submission form – Nelarabine	-	21oct10	Y 🗆	N 🗌	
	IMP Label RA submission form – Palifermin	-	21oct10	Y 🗌	N 🗌	
05	CORRESPONDENCE			1		
	UKALL14 Monitoring Plan	4.0	18oct16	Y 🗌	N 🗌	
	UKALL14 central monitoring checklists	-	-	Y 🗌	N 🗌	Please file all previous versions of checklists here
Please provide the email address of the person to whom updated documents should be sent: The completed form can be returned to ctc.ukall14@ucl.ac.uk or fax to 0207 679 9861 This is intended to support site's own internal systems for maintaining the PSF; therefore if the checklist is not returned to UCL CTC we will assume that documents contained within your PSF are up-to-date.						
	ollowing are general reminders re				File:	
	lder must be stored in a secure loo		opriate/restricted	access.		
The documents should be filed as per index. (CTC index or site's own index is acceptable)						
	nents generated locally (e.g. local a able sections.	approvals, IMP l	abels, prescriptior	ns, corres	onder	nce, etc.) must be filed in the
Where documents are held in an alternative location, file notes should be present to indicate this.						
Up-to-date CVs must be present for all site staff. (CVs should be signed & dated and updated regularly according to employing institution policy)						
GCP certificates must be present (or details of course attended listed in the CV) for all site staff. (All staff should have attended a course – frequency of repeat training may be dictated by the employing institution policy, or 2 yearly where the institution has no policy, and more frequently when there have been updates to the legal or						

regulatory requirements for conduct of clinical trials)